Form 4: Liquidia Corp Director Katherine Rielly-Gauvin Receives Equity Grant

Liquidia Corp's Director, Katherine Rielly-Gauvin, has been granted 18,396 restricted stock units, increasing her beneficial ownership in the company.

Summary

• Katherine Rielly-Gauvin, a Director of Liquidia Corp (LQDA), acquired 18,396 shares of common stock through the grant of Restricted Stock Units (RSUs).
• The transaction occurred on June 17, 2025.
• These RSUs convert into common stock on a one-for-one basis.
• Following this transaction, Ms. Rielly-Gauvin beneficially owns 38,755 shares of Liquidia Corp common stock.
• The RSUs will vest upon the earlier of the one-year anniversary of the grant date or the day prior to the Issuer's next annual shareholder meeting following the grant date.

Sentiment

Score: 7

Explanation: The grant of Restricted Stock Units to a director is a positive signal of continued alignment between management/board and shareholder interests, and is a standard component of director compensation. It does not, however, indicate any new operational or financial performance.

Positives

• The grant of 18,396 Restricted Stock Units (RSUs) to Director Katherine Rielly-Gauvin aligns her interests with those of shareholders, incentivizing long-term performance.
• The increase in beneficial ownership to 38,755 shares demonstrates continued commitment from a key board member.

Future Outlook

The document indicates that the granted Restricted Stock Units will vest upon the earlier of the one-year anniversary of the grant date (June 17, 2025) or the day prior to Liquidia Corp's next annual shareholder meeting following the grant date, aligning future compensation with company performance and tenure.

Industry Context

The grant of Restricted Stock Units (RSUs) is a common form of equity compensation for directors and executives in the biotechnology and pharmaceutical industries, aiming to align their long-term interests with shareholder value creation. This practice is standard across publicly traded companies to attract and retain talent.

Comparison to Industry Standards

• The grant of RSUs as a form of director compensation is a standard practice across the U.S. public company landscape, particularly in growth-oriented sectors like biotechnology.
• While specific grant sizes vary based on company size, director responsibilities, and compensation philosophy, this type of equity award is consistent with typical non-cash compensation structures for independent directors.
• Comparable companies in the biopharmaceutical sector often utilize similar RSU or stock option grants to incentivize board members, such as those seen at companies like United Therapeutics Corporation or Acceleron Pharma (prior to acquisition), where equity forms a significant portion of director remuneration.

Corporate Governance

Related Party Transactions

• The grant of Restricted Stock Units to Katherine Rielly-Gauvin, a Director of Liquidia Corp, constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director is intended to align the director's interests with those of shareholders, potentially leading to better long-term decision-making. However, it also represents a form of dilution as new shares will be issued upon vesting.

Next Steps

• The Restricted Stock Units (RSUs) are scheduled to vest upon the earlier of the one-year anniversary of the grant date (June 17, 2025) or the day prior to Liquidia Corp's next annual shareholder meeting following the grant date.

Key Dates

Recommendation

Keywords

Liquidia Corp, LQDA, SEC Form 4, Restricted Stock Units, RSU grant, Insider transaction, Equity compensation, Director compensation, Beneficial ownership, Corporate governance